Skip to main content
Article thumbnail
Location of Repository

Update on the management of neuromuscular block: focus on sugammadex

By Hans D de Boer, Jan van Egmond, Jacques J Driessen and Leo HD Booij

Abstract

Steroidal neuromuscular blocking agents (NMBAs), such as rocuronium, are widely used in clinical anesthesia and emergency medicine to facilitate endotracheal intubation and artificial ventilation and to allow surgical access to body cavities. Reversal of neuromuscular blockade is important for the acceleration of patient recovery and prevention of postoperative residual neuromuscular blockade and reduces the incidence of severe morbidity and mortality associated with anesthesia management. Sugammadex is the first selective relaxant binding agent (SRBA) and has been designed to reverse the steroidal neuromuscular blocking drug rocuronium. Encapsulation of the rocuronium molecule by sugammadex results in a rapid decrease in free rocuronium in the plasma and subsequently at the nicotinic receptor at the motor endplate. After encapsulation, rocuronium is not available to bind to the nicotinic receptor in the neuromuscular junction. This promotes the liberation of acetylcholine receptors, and muscle activity reappears. This new concept of reversal of neuromuscular block induced by rocuronium (or vecuronium) led to impressive results in animal and phase 1 and 2 studies. Sugammadex is currently in phase 3 clinical studies and may be commercially available by 2008

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2656290
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl,
    2. (1992). Anaesthetic practice and postoperative pulmonary complications. Acta Anaesthesiol Scand,
    3. (2006). Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys.
    4. (1996). Comparative use of muscle relaxants and their reversal in three European countries: a survey in France,
    5. (2005). Cyclodextrins in drug delivery: an updated review.
    6. (2003). Drug-specifi c cyclodextrins: the future of rapid neuromuscular block reversal. Drugs Future,
    7. (2007). Fast, effective and safe reversal of rocuronium and vecuronium-induced moderate neuromuscular block by the selective relaxant binding agent Org 25969. Anesthesiology,
    8. (2005). First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.
    9. (2005). Impact of anesthesia management characteristics on severe morbidity and mortality.
    10. (2003). Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial.
    11. (2002). Liquid chromatography/mass spectrometric bioanalysis of a modifi ed γ cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969.
    12. (1995). New neuromuscular blocking drugs.
    13. (2006). Org 25969 (sugamadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block.
    14. (2002). Org 25969 causes rapid reversal of rocuronium-induced neuromuscular block, independent of acid-base status.
    15. (2001). Org 25969 causes selective reversal of neuromuscular block induced by steroidal NMBs in anaesthetized guinea pigs.
    16. (2001). Org 25969 causes selective reversal of neuromuscular blockade induced by steroidal NMBs in the mouse hemi-diaphragm preparation.
    17. (2001). Org 25969 reverses rocuronium-induced neuromuscular blockade in the cat without important hemodynamic effects.
    18. (1993). Postoperative residual curarisation: incidence, aetiology and associated morbidity. Anaesth Intensive Care,
    19. (2003). Rapid reversal of rocuroniuminduced neuromuscular block by Org 25969 is independent of renal perfusion.
    20. (2002). Reversal agents for nondepolarizing neuromuscular blockade: reasons for and development of a new concept. Semin Anesth Periop Med Pain,
    21. (2005). Reversal by Org 25969 is not affected by sevofl urane when compared with propofol.
    22. (2005). Reversal of high dose rocuronium (1.2 mg/kg) with Org 25969.
    23. (2005). Reversal of high dose rocuronium with Org 25969.
    24. (2003). Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology,
    25. (2006). Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized Rhesus monkeys.
    26. (2005). Reversal of rocuroniuminduced (1.2 mg/kg) neuromuscular block by Org 25969: a multi-center dose fi nding and safety study. Anesthesiology,
    27. (2006). Reversal of rocuroniuminduced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study.
    28. (2006). Sugammadex reversal of rocuroniuminduced neuromuscular blockade: a comparision wth neostigmineglycopyrrolate and edrophonium-atropine.
    29. (2001). The cyclodextrin derivative Org 25969, which forms complexes with steroidal neuromuscular blocking agents, causes selective reversal of normal and profound neuromuscular block. Anesthesiology,
    30. (1997). The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg,

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.